Mainstay Capital Management’s Novo Nordisk NVO Stock Holding History

Mainstay Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,838	Closed	-$403K	–	142
2025 Q2	$403K	Buy	+5,838	New	+$397K	0.02%	116
2025 Q1	–	Sell	-2,566	Closed	-$221K	–	114
2024 Q4	$221K	Buy	2,566 +44	+2%	+$4.76K	0.03%	99
2024 Q3	$300K	Hold	2,522	–	–	0.05%	86
2024 Q2	$360K	Buy	2,522 +13	+0.5%	+$1.72K	0.06%	75
2024 Q1	$322K	Buy	2,509 +49	+2%	+$5.83K	0.06%	85
2023 Q4	$254K	Buy	+2,460	New	+$243K	0.05%	94
2023 Q3	–	Sell	-2,670	Closed	-$216K	–	105
2023 Q2	$216K	Buy	+2,670	New	+$218K	0.04%	101

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mainstay Capital Management's NVO Position: Q3 2025 in Review

Mainstay Capital Management sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 5,838 shares — an estimated $403K sold.

Mainstay Capital Management first reported a position in NVO in Q2 2023 and held it in 7 quarters. The position peaked at $403K in Q2 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Mainstay Capital Management reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Mainstay Capital Management sold 5,838 Novo Nordisk shares in Q3 2025, an estimated $403K.
Mainstay Capital Management first reported a position in Novo Nordisk in Q2 2023 and held it in 7 quarters.
Mainstay Capital Management's Novo Nordisk position peaked at $403K in Q2 2025.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Mainstay Capital Management's 13F filing for Q3 2025, filed 10 Dec 2025.